'New era' in Alzheimer's disease treatment as second drug approved in US

Drug was approved for use by the US Food and Drug Administration this week for patients with mild cognitive impairment or mild dementia stage of disease. File picture

A new treatment for slowing the impact of early Alzheimer’s disease has been approved in the US and welcomed by the Alzheimer Society of Ireland.

This follows earlier American approval of a drug called Lecanemab, which is already under assessment for use in Europe.